Santhera Pharmaceuticals Holding AG SANN

SWX: SANN | ISIN: CH0027148649   17/05/2024
9,250 CHF (-0,96%)
(-0,96%)   17/05/2024

25 april 2024 · Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May · Persbericht

27 maart 2024 · Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA · Persbericht

14 maart 2024 · Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States · Persbericht

14 februari 2024 · Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology · Persbericht

15 januari 2024 · Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy · Persbericht

12 januari 2024 · Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom · Persbericht

18 december 2023 · Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy · Persbericht

7 december 2023 · Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage · Persbericht

27 oktober 2023 · Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy · Persbericht

13 oktober 2023 · Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy · Persbericht

7 september 2023 · Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update · Persbericht

31 juli 2023 · Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group · Persbericht

19 juli 2023 · Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone · Persbericht

29 juni 2023 · Santhera Publishes Timeline of the Reverse Share Split · Persbericht

27 juni 2023 · Shareholders Approve all Board Proposals at Today’s Annual General Meeting · Persbericht

20 juni 2023 · Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties · Persbericht

6 juni 2023 · Santhera Publishes Agenda for its Annual General Meeting · Persbericht

31 mei 2023 · Santhera Publishes Annual Report 2022 · Persbericht

27 april 2023 · Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update · Persbericht

25 april 2023 · Vamorolone NDA mid-cycle review meeting by FDA completed · Persbericht

Mijn selecties